

Oncology
LettersInternational
Journal
of OncologyMolecular
and Clinical
OncologyExperimental
and Therapeutic
MedicineInternational
Journal
of Molecular
MedicineBiomedical
ReportsOncology
ReportsMolecular
Medicine
Reports

Oncology Reports

[Journal Home](#)[Current Issue](#)[Early Online](#)[Most Read](#)[Archive](#)[Information](#)[Online Submission](#)[Information for
Authors](#)[Language Editing](#)[Information for
Reviewers](#)[Editorial Policies](#)[Editorial Board](#)[Aims and Scope](#)[Abstracting and
Indexing](#)[Bibliographic
Information](#)[Information for
Librarians](#)[Information for
Advertisers](#)[Reprints and
permissions](#)[Contact the Editor](#)[General
Information](#)[About Spandidos
Conferences](#)

Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor

Authors: Benford Mafuvadze, Yayun Liang, Salman M. Hyder[View Affiliations](#)**Published online on:** Tuesday, July 15, 2014**DOI:** 10.3892/or.2014.3332

Abstract

Breast cancer cells express enzymes that convert cholesterol, the synthetic precursor of steroid hormones, into estrogens and androgens, which then drive breast cancer cell proliferation. In the present study, we sought to determine whether oxidosqualene cyclase (OSC), an enzyme in the cholesterol biosynthetic pathway, may be targeted to suppress progression of breast cancer cells. In previous studies, we showed that the OSC inhibitor RO 48-8071 (RO) may be a ligand which could potentially be used to control the progression of estrogen receptor- α (ER α)-positive breast cancer cells. Herein, we showed, by real-time PCR analysis of mRNA from human breast cancer biopsies, no significant differences in OSC expression at various stages of disease, or between tumor and normal mammary cells. Since the growth of hormone-responsive tumors is ER α -dependent, we conducted experiments to determine whether RO affects ER α . Using mammalian cells engineered to express human ER α or ER β protein, together with an ER-responsive luciferase promoter, we found that RO dose-dependently inhibited 17 β -estradiol (E2)-induced ER α responsive luciferase activity (IC₅₀ value, ~10 μ M), under conditions that were non-toxic to the cells. RO was less effective against ER β -induced luciferase activity. Androgen receptor (AR) mediated transcriptional activity was also reduced by RO. Notably, while ER α activity was reduced by atorvastatin, the HMG-CoA reductase inhibitor did not influence AR activity, showing that RO possesses broader antitumor properties. Treatment of human BT-474 breast cancer cells with RO reduced levels of estrogen-induced PR protein, confirming that RO blocks ER α activity in tumor cells. Our findings demonstrate that an important means by which RO suppresses hormone-dependent growth of breast cancer cells is through its ability to arrest the biological activity of ER α . This warrants further investigation of RO as a potential therapeutic agent for use against hormone-dependent breast cancers.

Journal Cover

Print ISSN: 1021-335X
Online ISSN: 1791-2431
2013 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)
[Sign up for eToc alerts](#)
[Recommend to Library](#)

Article Options

Viewing Options[View Abstract](#)[Purchase PDF](#)**Citations**[Cite This Article](#)[Cited By](#)**Related Articles**[on Google Scholar](#)[on Pub Med](#)**Copyright**[© Get Permissions](#)

Job Opportunities

Contact

Terms and
Conditions



Copyright © Spandidos Publications 2014. All rights reserved.

[About](#) | [Contact](#) | [Help](#) | [Cookie Policy](#) | [Privacy Policy](#)

